USA Assisted Reproductive Technology Market Outlook to 2028

USA Assisted Reproductive Technology Market Overview

The USA Assisted Reproductive Technology (ART) Market was valued at USD 5.74 billion in 2023, driven by advancements in medical technology, increased awareness about fertility treatments, and rising infertility rates. The growing acceptance of ART procedures, coupled with supportive government policies and an aging maternal age demographic, has fueled market growth.

Key players in the USA ART market include Cooper Surgical, Vitrolife AB, Cook Medical, Ferring Pharmaceuticals, and Merck KGa A. These companies dominate the market through comprehensive service offerings, innovative fertility treatment solutions, and strategic collaborations that enhance patient outcomes and service accessibility.

The market in the USA is predominantly concentrated in states like California, New York, and Texas, which lead in ART adoption due to their advanced healthcare infrastructure, high patient awareness, and availability of specialized fertility centers.

In 2023, Cooper Surgical launched a new time-lapse imaging system, Embryo Scope+ that integrates AI technology to enhance embryo selection processes, optimizing IVF success rates. This innovation is expected to improve ART outcomes and expand Cooper Surgicals market reach.

USA Assisted Reproductive Technology Market Segmentation

The USA ART market is segmented by various factors, including procedure type, end-user, and region.

By End-User: The market is segmented by end-user into fertility clinics, hospitals. Fertility clinics dominated the market in 2023, driven by specialized facilities, expert medical staff, and a focused approach to reproductive treatments. The rise in infertility rates and the need for specialized care have fueled demand in this segment. Growth is supported by advanced technologies like genetic screening and embryo selection techniques that enhance success rates and patient satisfaction.

By Procedure Type: The market is segmented into in vitro fertilization (IVF), artificial insemination, surrogacy. In 2023, IVF held the dominant market share due to its high success rates and widespread use in treating various fertility issues. IVF procedures include traditional IVF, ICSI (Intracytoplasmic Sperm Injection), and frozen embryo transfer, with leading providers like Vitrolife AB and Cook Medical establishing a strong presence in this segment, contributing to its dominance.

By Region: The market is regionally segmented into Northeast, Midwest, South, and West USA. In 2023, the West USA dominated the market share, primarily due to the presence of advanced healthcare infrastructure, a higher number of fertility centers, and supportive state policies. The Northeast USA follows closely, with substantial adoption driven by higher patient awareness and robust healthcare systems.

USA Assisted Reproductive Technology Market Competitive Landscape

Company

Establishment Year

Headquarters

Cooper Surgical

1989

Trumbull, Connecticut

Vitrolife AB

1994

Gothenburg, Sweden

Cook Medical

1963

Bloomington, Indiana

Ferring Pharmaceuticals

1950

Saint-Prex, Switzerland

Merck KGa A

1668

Darmstadt, Germany

Cooper Surgical: In 2023, Cooper Surgical acquired Zy Mt Fertility, a subsidiary of Dx Now, Inc., for an undisclosed amount.This acquisition strengthens Cooper Surgical's portfolio of innovative solutions for reproductive care and enhances patient outcomes. Zy Mt Fertility develops and commercializes a first-of-its-kind sperm separation device for use in artificial or assisted reproductive therapies.

Vitrolife AB: In 2023, Vitrolife AB launched Gx Media, which includes triple antioxidant protection aimed at improving embryo viability. This product is part of their broader strategy to enhance ART outcomes and solidify their position in the ART market. The introduction of Gx Media aligns with their goal of providing superior products that contribute to higher success rates in IVF, thereby supporting ART clinics and improving patient outcomes

USA Assisted Reproductive Technology Market Analysis

Growth Drivers

Increasing Maternal Age and Infertility Rates: The rise in maternal age is a noteworthy growth driver in the market. According to the Centers for Disease Control and Prevention (CDC), in 2022, the mean age of mothers at first birth increased to 27.4 years, another record high. This trend correlates with a higher incidence of infertility, as fertility rates typically decline after age 35. This demographic shift, combined with societal trends towards delayed parenthood, is driving the market's expansion as more couples seek fertility solutions.

Advancements in ART Technologies and Success Rates: Technological advancements have boosted ART success rates, making treatments more appealing to potential patients. The integration of AI in embryo selection has improved the accuracy of identifying viable embryos, AI models had a median accuracy of 77.8% in predicting clinical pregnancy, compared to 64% by embryologists. Moreover, innovations like pre-implantation genetic testing (PGT) have reduced miscarriage rates by detecting genetic abnormalities early, thus enhancing patient outcomes.

Insurance Coverage Expansion and Cost Reduction Initiatives: The expansion of insurance coverage for ART procedures is another critical growth driver. As of 2024, majority of states in the USA mandate insurance coverage for at least some ART services, according to the US Department of Health and Human Services. This expansion has reduced the financial burden on patients, making treatments like IVF more accessible to a broader population. Additionally, some states have introduced cost-sharing initiatives, lowering out-of-pocket expenses for patients.

Challenges

High Treatment Costs and Limited Accessibility: Despite expanded insurance coverage, the high cost of ART treatments remains an important barrier. The cost of a single IVF cycle in the USA is high, excluding additional expenses for medications. This financial burden makes ART procedures inaccessible to many middle- and lower-income families. Many couples who could benefit from ART do not pursue treatment due to these high costs, highlighting a major challenge for market growth.

Ethical and Legal Concerns: The market faces numerous ethical and legal challenges that complicate its growth. Surrogacy and embryo handling laws vary across states, with some states having strict regulations that limit the availability of these services. Legal disputes over embryo ownership and surrogacy contracts create uncertainties for both providers and patients, potentially deterring the adoption of ART services in certain regions.

Government Initiatives

Family Building Act of 2024: The Family Building Act, introduced in 2024, aims to enhance access to fertility treatments by providing federal grants and tax credits to individuals undergoing ART procedures. The act mandates that all state insurance programs cover at least one IVF cycle, expanding accessibility for low- and middle-income families. According to the US Department of Health and Human Services, this initiative has led to substantial increase in the number of insured ART cycles in the first half of 2024 alone.

Reproductive Health Equity Act 2024: The Reproductive Health Equity Act, introduced in 2024, aims to ensure equitable access to ART services for all individuals, regardless of socioeconomic status or geographic location. The act mandates federal funding to establish new ART clinics in underserved areas and provides grants to existing clinics to expand their services. It also includes provisions for comprehensive insurance coverage for ART procedures across all states.

USA Assisted Reproductive Technology Future Market Outlook

The USA ART market is poised for substantial growth, driven by technological advancements in reproductive medicine, increasing acceptance of fertility treatments, and supportive government policies.

Future Market Trends

Expansion of Genetic Screening and AI Integration: By 2028, genetic screening and AI integration in ART processes are expected to become standard practices, improving success rates and patient outcomes. The use of AI for personalized treatment plans and optimized embryo selection will drive substantial investments in ART technologies.

Growth in Surrogacy and Egg Donation Services: With rising awareness and acceptance, surrogacy and egg donation services are projected to grow significantly by 2028. This growth is driven by changing social norms, supportive legislation, and increased demand from same-sex couples and single parents.
Please Note: It will take 5-7 business days to complete the report upon order confirmation